Cyclerion Therapeutics Inc (CYCN)
3.00
0.00 (0.00%)
USD |
NASDAQ |
May 10, 16:00
3.00
0.00 (0.00%)
After-Hours: 20:00
Cyclerion Therapeutics Enterprise Value: 0.5593M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 0.5593M |
| May 08, 2024 | 0.2018M |
| May 07, 2024 | 0.1257M |
| May 06, 2024 | 0.1257M |
| May 03, 2024 | 0.4373M |
| May 02, 2024 | 0.0715M |
| May 01, 2024 | 0.6677M |
| April 30, 2024 | 0.0986M |
| April 29, 2024 | 0.7761M |
| April 26, 2024 | 0.3696M |
| April 25, 2024 | 0.6677M |
| April 24, 2024 | -0.064M |
| April 23, 2024 | 0.6948M |
| April 22, 2024 | 0.6948M |
| April 19, 2024 | 1.914M |
| April 18, 2024 | 1.151M |
| April 17, 2024 | 1.151M |
| April 16, 2024 | 1.047M |
| April 15, 2024 | 1.426M |
| April 12, 2024 | 1.562M |
| April 11, 2024 | 0.6937M |
| April 10, 2024 | 0.8303M |
| April 09, 2024 | 0.5864M |
| April 08, 2024 | 1.101M |
| April 05, 2024 | 1.372M |
| Date | Value |
|---|---|
| April 04, 2024 | 1.616M |
| April 03, 2024 | 0.9929M |
| April 02, 2024 | 0.9929M |
| April 01, 2024 | 0.749M |
| March 28, 2024 | 1.101M |
| March 27, 2024 | 0.7767M |
| March 26, 2024 | 0.7761M |
| March 25, 2024 | 0.6406M |
| March 22, 2024 | 0.6948M |
| March 21, 2024 | 1.101M |
| March 20, 2024 | 1.372M |
| March 19, 2024 | 0.8303M |
| March 18, 2024 | 1.101M |
| March 15, 2024 | 1.237M |
| March 14, 2024 | 1.535M |
| March 13, 2024 | 0.5867M |
| March 12, 2024 | 0.5596M |
| March 11, 2024 | 0.8357M |
| March 08, 2024 | 0.9119M |
| March 07, 2024 | 0.8303M |
| March 06, 2024 | 0.0173M |
| March 05, 2024 | 0.284M |
| March 04, 2024 | 1.101M |
| March 01, 2024 | 1.006M |
| February 29, 2024 | 0.5593M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-67.59M
Minimum
Nov 15 2019
420.07M
Maximum
May 22 2019
44.49M
Average
13.16M
Median
Sep 19 2022
Enterprise Value Benchmarks
| Eli Lilly and Co | 757.00B |
| iBio Inc | 16.42M |
| AbbVie Inc | 339.22B |
| Agile Therapeutics Inc | 1.720M |
| NovaBay Pharmaceuticals Inc | 2.645M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.694M |
| Total Expenses (Quarterly) | 1.795M |
| EPS Diluted (Quarterly) | -0.70 |
| Earnings Yield | -100.3% |
| Normalized Earnings Yield | -793.43 |